4th Annual MarketsandMarkets Epigenetics Congress

While most of the molecular studies focus over mutational analysis, epigenetics-is the only science which is gaining momentum with its cheaper and faster technology, by making its way to the clinic. Moving on the path of clinical epigenetics, this congress will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.

Learn from academia and industry experts about clinical epigenetics, discussing solutions to challenges like drug discovery, identification of molecular inhibitors, gene modification and analysis.

Our expert speaker panel will address emergence of novel drugs and next-generation diagnostic technologies with respect to huge growth, government funding for epigenetics research. The congress will host effective mix of case studies, panel discussion and presentations on development of epigenetics, translational epigenetics, clinical epigenetics and more.

Engage with pioneers and leaders from academia and industry and stay updated with the latest advancement in epigenetics research right from drug discovery to identification of molecular inhibitors to gene modifications and analysis.

Heads, Directors, Group Leaders, Professors, Lecturers, Research Associates, Scientists, Investigators, Fellows, Readers from Pharmaceutical, Bio-pharmaceutical and Research Institutes

CONFERENCE AGENDA

Registration	08:00 - 08:55
Welcome note from MarketsandMarkets	08:55 - 09:00
Opening Remarks from the Chairman Ronan Murphy , Assciate Editor, Clinical Epigenetics , Dublin City University	09:00 - 09:05
DEVELOPMENT OF EPIGENETICS
Emerging Portfolio of Novel Epigenetic Inhibitors Daniel Dransfield, Vice President, Biology, Epizyme	09:05 - 09:40
High-resolution economical profiling of epigenetic DNA modifications using TOP-seq Saulius Klimasauskas, Director and Distinguished Professor, Institute of Biotechnology, Vilnius University	09:40 - 10:15
Robst Sample Preparation Solutions for Chromatin-based Applications Angela Garding, Field Application Scientist, Covaris	10:15 - 10:45
Morning Refreshments \| Poster Presentations \| One-to-One Networking	10:45 - 11:35
The Potential of Select BET Inhibition for High Risk Vascular Diseases Kenneth Lebioda, Senior Vice President, Business & Corporate Development, Reservlogix	11:35 - 12:05
Importance of investigating epigenetic alterations for industry and regulators Rémi Terranova , Principle Investigator, Preclinical safety, Novartis Institutes for BioMedical Research, Switz	12:05 - 12:40
Drugging transcription: Progress and potential for treating human immune dysfunction Inma Rioja , Senior Director & Portfolio Research Lead at Epige, GSK	12:40 - 13:10
Lunch \| Poster Presentations \| One-to-One Networking	13:10 - 14:10
TRANSLATIONAL EPIGENETICS
Development of novel therapeutic anticancer approach with HDAC inhibitors: from the bench to the bedside Alfredo Budillon , Chief Experimental Pharmacology Unit Department of, Istituto Nazionale tumori G. Pascale	14:10 - 14:45
Selective’ targeting of transcriptional scaffolding Panagis Filippakopoulos , Associate Professor, Structural Genomics Consortiu, University of Oxford	14:45 - 15:20
Evening Refreshments \| Poster Presentations \| One-to-One Networking	15:20 - 16:10
Platelets: Functional biomarkers of epigenetic drift Ronan Murphy , Assciate Editor, Clinical Epigenetics , Dublin City University	16:10 - 16:45
Making sense of disease-linked non-coding mutations Mikhail Spivakov , Group leader and Honorary Senior Lecturer, MRC Lon, Imperial College	16:45 - 17:20
Probing HDACs and bromodomains in cancer with small molecule designer libraries John Spencer, Professor, Bioorganic Chemistry, University of Sussex	17:20 - 17:55
Closing Remarks by the Chair	17:55 - 18:00
End of Day 1	18:00 - 18:10
Drink Reception & Networking	18:00 - 19:00

Registration	08:15 - 08:55
Welcome note from MarketsandMarkets	08:55 - 09:00
Opening Remarks from the Chairman Dr. Tamara Maes , Chief Scientific Officer, Oryzon, Spain	09:00 - 09:10
CLINICAL EPIGENETICS
Histone demethylase inhibitors in CNS and oncology- LSD1 inhibitors iadademstat and vafidemstat from bench to bedside Dr. Tamara Maes , Chief Scientific Officer, Oryzon, Spain	09:05 - 09:40
Epigenetic in drug development: a discovery safety perspective Ambra Bianco, Associate Principal Scientist, AstraZeneca	09:40 - 10:15
The epigenetic protein SP140 directs inflammatory activation of macrophages in crohn’s disease Mohammed Ghiboub, Researcher, Amsterdam UMC	10:15 - 10:50
Morning Refreshments \| Poster Presentations \| One-to-One Networking	10:50 - 11:40
DNA methylation as an epigenetic factor in psychiatric disorders and their treatment Gavin Reynolds , Professor Emeritus , Queens University Belfast	11:40 - 12:15
Challenges in targeting histone demethylases Christopher Schofield , Head of Organic Chemistry, University of Oxford and fellow of Royal society,	12:15 - 12:50
Lunch \| Poster Presentations \| One-to-One Networking	12:50 - 13:50
Pancreatic islet chromatin dynamics and type 1 diabetes genetic architecture Lorenzo Pasquali, Group Leader of the Endocrine Regulatory Genomics laboratory, IGTP	13:50 - 14:25
Using imaging flow cytometry for epigenetics studies and drug development Ziv Porat, Staff Scientist, Weizmann Institute	14:25 - 15:00
Closing remarks by Chairperson	15:00 - 15:05
End of Conference	15:05 - 15:10